CLEVELAND, Ohio — Leishmaniasis is a disfiguring parasitic disease that affects millions of people globally, including in the United States. Currently, there is no vaccine to protect against the ...
The firm recently advanced its first candidate into clinical testing, evaluating STX-1150 as a treatment for hypercholesterolemia.
Riverside Homestead on MSNOpinion
A California wildfire hit 0% containment - then the forecast map already had the West marked, "Where the West might burn"
The strongest political angle is that ordinary people are being asked to absorb the cost and risk of systems they did not ...
Scribe Therapeutics’ pipeline is immature, with its lead program recently greenlit for first-in-human testing. The biotech is working on CRISPR-based therapies for cardiometabolic diseases. Scribe ...
One company leads in gene-editing approvals, while the other targets surging demand in metabolic treatments. Here’s how their financials and risk profiles compare.
Vertex has secured a label expansion through the FDA's Commis | Vertex Pharmaceuticals has gained a label expansion from the ...
The California drugmaker, which has collaborations in place with Biogen, Sanofi and Eli Lilly, could be the 14th biotech to ...
Scribe Therapeutics is the latest biotech to prepare a public listing, as the company looks to propel its lipid-lowering medicines through clinical trials. While the Bay Area biotech has yet to set ...
Casgevy sickle cell gene therapy is now FDA-approved for children as young as two, opening access for 5,500 more U.S. kids.
Recent data published in NEJM demonstrates that CRISPR gene-editing therapy achieves complete clinical efficacy endpoints in ...
A UCLA study has identified a hidden Achilles' heel in aggressive small cell cancers that have resisted new treatments for ...
In a study published in Science Translational Medicine, a team of researchers led by Dr. Wang Yu from the Shenzhen Institutes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results